BMS Appoints EVP, CSO

From DCAT Value Chain Insights (VCI)

By People On The Move posted 03-13-2017 10:01


Bristol-Myers Squibb (BMS) has appointed Dr. Thomas Lynch to executive vice president and chief scientific officer, effective March 16, 2017. He succeeds Dr. Francis Cuss, who will retire from the company.

Dr. Cuss will serve as an advisor to the company for the next three months to ensure a seamless transition. In connection with the new appointment, Dr. Lynch will step down from the BMS board of directors, effective March 15, 2017.

Dr. Lynch has served as chairman and chief executive officer of Massachusetts General Physicians Organization and a member of the Massachusetts General Hospital Board since 2015. From 2009 to 2015, Dr. Lynch was director of Yale Cancer Center and was the Richard and Jonathan Sackler Professor of Internal Medicine, Yale Cancer Center, Yale School of Medicine. He has also served as the physician in chief of Smilow Cancer Hospital, Yale-New Haven, since 2009. Prior to 2009, Dr. Lynch was professor of medicine at Harvard Medical School and chief of Hematology/Oncology at Massachusetts General Hospital. Dr. Lynch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.

Source: Bristol-Myers Squibb


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription